权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

An implantable hemodialyzer for treatment of End-Stage Renal Disease

用于治疗终末期肾病的植入式血液透析器

基本信息

批准号：
8714973
负责人：
Charles Blaha
金额：
$ 22.51万
依托单位：
SILICON KIDNEY, LLC
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-07-01 至 2017-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8714973
关键词：
Adoption Affect Anemia Biocompatible Biological Markers Blood Blood Platelets Blood Vessels Blood coagulation Blood flow C-reactive protein Canis familiaris Cannulations Cardiovascular system Caregivers Complex Data Deposition Devices Dialysis procedure Disease Outcome End stage renal failure Expenditure FDA approved Fracture Goals Haptoglobins Health Health Benefit Hemodialysis Hemolysis Home Hemodialysis Home environment Housing Implant In Vitro Inflammation Interleukin-6 Kidney Kidney Transplantation Life Mechanics Medicare Membrane Metabolism Minerals Modeling Needlestick Injuries Outcome Patients Performance Phase Physiology Population Property Proteins Pump Quality of life Risk Risk Reduction Self Care Side Silicon Sleep Small Business Innovation Research Grant Survival Rate System Technology Testing Thrombosis Thrombus United States United States National Institutes of Health Urea Venous biomaterial compatibility cost design empowered fluid flow improved lactate dehydrogenase 3 nanopore performance tests phase 2 study

项目摘要

DESCRIPTION (provided by applicant): End-Stage Renal Disease (ESRD) affects just over 600,000 people in the United States and costs Medicare ~$33 billion annually. In-center thrice-weekly hemodialysis is the most commonly performed treatment for ESRD, but it suffers from poor 5-year survival rates, reduced patient quality of life, and is costly. In contrast, daily-extended hemodialysis has demonstrated 5-year survival rates similar to kidney transplant and has improved intermediate outcomes. Even though daily-extended hemodialysis yields superior outcomes than in- center thrice-weekly hemodialysis, it is performed by less than 1% of the ESRD population because it is too costly to perform in-center and too complex to perform at home. Current home hemodialysis systems require patients and caregivers to perform complicated tasks associated with life threatening risks, such as self-care needle sticks. The superior outcomes but low adoption rate of daily-extended home hemodialysis creates an opportunity for a simple-to-use and safe home hemodialysis system. The long-term objective of our project is to create a new home hemodialysis system (nHHD) that will increase the practice of daily-extended home hemodialysis and improve End-Stage Renal Disease (ESRD) outcomes. This NIH SBIR Phase I proposal aims to demonstrate the feasibility of the nHHD that will empower ESRD patients to perform daily-extended home hemodialysis and consequently receive the associate health benefits.

描述（由申请人提供）：终末期肾病（ESRD）在美国影响超过60万人，每年花费医疗保险约330亿美元。每周一次的中心血液透析是ESRD最常用的治疗方法，但其5年生存率较低，降低了患者的生活质量，而且费用昂贵。相比之下，每日延长血液透析的5年生存率与肾移植相似，并改善了中期预后。尽管每日延长的血液透析比每周三次的中心血液透析效果更好，但只有不到1%的ESRD患者进行，因为在中心进行血液透析太昂贵，而且在家中进行血液透析太复杂。目前的家庭血液透析系统需要患者和护理人员执行与危及生命的风险相关的复杂任务，例如自我护理针头。每日延长家庭血液透析的良好效果但采用率低，为简单使用和安全的家庭血液透析系统创造了机会。我们项目的长期目标是创建一种新的家庭血液透析系统（nHHD），这将增加每日延长家庭血液透析的实践，并改善终末期肾病（ESRD）的结果。这项NIH SBIR I期提案旨在证明nHHD的可行性，这将使ESRD患者能够进行每日延长的家庭血液透析，从而获得相关的健康益处。